Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.41 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102650 | 0.92 | ESR1 (0.51) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL12886822 | 0.91 | MAPT (0.40) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL1102644 | 0.91 | ESR1 (0.53) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL134057 | 0.91 | ESR1 (0.52) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL13098744 | 0.91 | ESR1 (0.52) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL29444817 | 0.91 | ESR1 (0.52) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL12887159 | 0.91 | MAPT (0.39) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL25668057 | 0.90 | MEN1 (0.52) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL24811898 | 0.90 | ESR1 (0.51) | MAPTMEN1HSP90AA1KMT2AESR1 | |
| SCHEMBL24810896 | 0.89 | MDM2 (0.52) | MAPTMEN1HSP90AA1KMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | MAPT 3162/4885MEN1 4462/4885HSP90AA1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.